OTC:INTI
Inhibitor Therapeutics, Inc.
A clinical-stage biotech firm pursuing innovative cancer therapies with significant cash reserves but no current product sales.
Key Metrics
Investment Thesis
Bull Case
Investors may view this stock as a high-risk, high-reward opportunity given the company's substantial paid-in capital of over $54 million providing significant financial runway. Successful progression of its oncology pipeline into late-stage trials could unlock significant value through potential FDA approval and partnership deals. The small market cap allows for outsized percentage gains if a key clinical milestone is achieved.
Bear Case
The absence of revenue and persistent net losses suggest the company cannot yet generate self-sustaining cash flow without further capital raises. Significant accumulated retained earnings deficits indicate that previous financing rounds have been consumed by development costs without commercial return. Investors should exercise caution due to the binary nature of biotech investments where a single failed trial can render the asset worthless.
About Inhibitor Therapeutics, Inc.
Inhibitor Therapeutics is a biotechnology company focused on developing novel therapeutics to treat cancer and other serious diseases. The company primarily serves the global oncology market through its pipeline of investigational drugs targeting specific molecular pathways. While currently without commercial revenue, the firm leverages strategic partnerships to advance its research and development programs.
Analysis
Management Discussion
The company reported a net loss of $3.3 million in 2024, driven by operating expenses of $3.7 million which include $1.7 million allocated to research and development. Despite a cash flow from operations deficit of $3.2 million, the firm maintained a positive cash balance of $5.6 million against total liabilities of $3.7 million. The income tax benefit of approximately $0.3 million reflects the company's pre-profit status.
Industry Overview
The global oncology sector is highly competitive and capital-intensive, with investors demanding proof of concept before valuations appreciate significantly. Companies in this space often operate at a loss during clinical development phases while waiting for regulatory approval to generate sales. Success depends on differentiating from large pharma competitors who have deeper pockets and established distribution networks.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $657.9K | $3.4M | $3.7M |
| Operating Income | $-657.9K | $-3.4M | $-3.7M |
| R&D | $6.2K | $1.4M | $1.7M |
| G&A | $651.8K | $2.0M | $2.0M |
| Stock-Based Comp | — | $13.8K | $40.2K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $12.8M | $378.8K | $0 |
| Interest Expense | $23.2K | — | — |
| Pre-Tax Income | $12.2M | $-3.0M | $-3.7M |
| Income Tax | $55.1K | $0 | $-318.2K |
| Continuing Ops | $12.1M | $-3.0M | $-3.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $12.1M | $-3.0M | $-3.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $12.1M | $-3.0M | $-3.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $12.0M | $8.9M | $5.7M |
| Cash & Equivalents | $12.0M | $8.8M | $5.6M |
| Prepaid Expenses | — | $109.2K | $87.8K |
| Other Current Assets | $23.9K | $0 | $0 |
| Long-Term Assets | $0 | $0 | $0 |
| Total Assets | $12.0M | $8.9M | $5.7M |
| Current Liabilities | $678.8K | $665.2K | $709.6K |
| Accounts Payable | $145.2K | $33.7K | $15.9K |
| Other Current Liab | $411.0K | $0 | $0 |
| Long-Term Liabilities | $3.0M | $3.0M | $3.0M |
| Total Liabilities | $3.7M | $3.7M | $3.7M |
| Shareholders' Equity | $8.3M | $5.3M | $2.0M |
| Paid-In Capital | — | $54.0M | $54.1M |
| Retained Earnings | $-45.8M | $-48.8M | $-52.1M |
| Total L&E | $12.0M | $8.9M | $5.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $12.1M | $-3.0M | $-3.3M |
| Non-Cash Adjustments | $-499.2K | $-156.9K | $83.1K |
| Working Capital Changes | $133.6K | $482.7K | $23.0K |
| Cash from Operations | $11.7M | $-2.7M | $-3.2M |
| Cash from Investing | $0 | $0 | — |
| Cash from Financing | $180.0K | $-411.0K | — |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $11.9M | $-3.1M | $-3.2M |
| Beginning Cash | $30.6K | $12.0M | $8.8M |
| Ending Cash | $12.0M | $8.8M | $5.6M |
Frequently Asked Questions
How does Inhibitor Therapeutics, Inc. make money?
The company's operations are centered entirely on Research and Development for its oncology pipeline. A second segment involves strategic collaborations and licensing agreements intended to offset high burn rates. The third area is Pre-Commercial Activities, encompassing regulatory filings and clinical trial management costs.
What are the main risks for INTI?
The lack of commercial revenue makes the company entirely dependent on external funding or successful clinical outcomes to sustain operations. High operating expenses and accumulated retained earnings deficits indicate significant burn rates typical of early-stage biotech firms. Clinical trial failures could lead to total loss of invested capital, potentially requiring dilutive equity offerings. Regulatory hurdles in oncology are stringent and time-consuming, delaying potential market entry.
What is INTI's competitive advantage?
The company possesses a differentiated portfolio of proprietary molecules targeting hard-to-treat cancer indications. Its strong balance sheet, evidenced by substantial paid-in capital relative to current liabilities, provides runway for long-term development. Strategic partnerships with established pharmaceutical entities offer potential milestone payments and validation of the technology platform.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.